Eyepoint Pharmaceuticals Inc (EYPT) Stock Price, Quote & News

Company Profile

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 926 5000

Fax: 617 926 5050

Website: eyepointpharma.com

Address:

480 Pleasant Street, Suite A-210, Watertown, United States

rizzato Sep. 14 at 11:48 AM

$EYPT https://stockinvest.us/stock/EYPT

0 · Reply

rizzato Sep. 12 at 7:18 AM

$EYPT no comment that is a silent forum

1 · Reply

rizzato Sep. 11 at 8:02 PM

$EYPT again today at 15.45 volume was 842.000 pcs at 16.00 volume was 1.180.000 any idea ?

0 · Reply

rizzato Sep. 11 at 5:18 PM

$EYPT high volume someone is adding more at these price as soon as they will be ready we will continue our up movement

0 · Reply

Poet5 Sep. 11 at 5:08 PM

$EYPT Now, that was a nice 250K sh buy at 12:54PM. More to come! Watch!

0 · Reply

rizzato Sep. 11 at 8:56 AM

$EYPT hi Guido I realized that , there should be something coming soon . I ask and answer myself hahahahahahhaha

0 · Reply

rizzato Sep. 10 at 8:02 PM

$EYPT did anyone of you notice that are 3 days in a row that at the closing time there are around 200.000 pcs bought

0 · Reply

rizzato Sep. 10 at 7:38 PM

$EYPT even if is an healthy drop it was better to avoid it

0 · Reply

rizzato Sep. 10 at 5:01 PM

$EYPT for the moment it could be considered an healthy drop I was waiting for it

0 · Reply

rizzato Sep. 10 at 1:24 PM

anyone has the open order book 10 levels to post? $EYPT

0 · Reply

EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 7:00 AM EDT - 19 days ago

EyePoint Announces Participation at Upcoming Investor Conferences

Aug 18, 2025, 4:01 PM EDT - 27 days ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 6, 2025, 4:09 PM EDT - 5 weeks ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:30 AM EDT - 5 weeks ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:00 AM EDT - 5 weeks ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Jul 30, 2025, 7:00 AM EDT - 6 weeks ago

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 29, 2025, 7:00 AM EDT - 6 weeks ago

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Jun 12, 2025, 11:03 AM EDT - 3 months ago

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

May 27, 2025, 7:00 AM EDT - 3 months ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 16, 2025, 7:00 AM EDT - 4 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 7, 2025, 2:49 PM EDT - 4 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 4 months ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Apr 30, 2025, 7:00 AM EDT - 4 months ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 27, 2025, 7:00 AM EDT - 6 months ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 5, 2025, 2:51 PM EST - 6 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 7:00 AM EST - 6 months ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Feb 26, 2025, 7:00 AM EST - 7 months ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

Feb 25, 2025, 7:00 AM EST - 7 months ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:39 PM EST - 8 months ago

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

Jan 30, 2025, 7:00 AM EST - 8 months ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 8, 2025, 7:00 AM EST - 8 months ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Dec 4, 2024, 7:00 AM EST - 10 months ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Nov 14, 2024, 5:04 AM EST - 10 months ago

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 4, 2024, 7:00 AM EST - 11 months ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Oct 31, 2024, 4:00 PM EDT - 11 months ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 29, 2024, 9:47 PM EDT - 11 months ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 28, 2024, 5:14 PM EDT - 11 months ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 7:00 AM EDT - 11 months ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 24, 2024, 7:00 AM EDT - 11 months ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Sep 4, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Aug 29, 2024, 5:35 PM EDT - 1 year ago

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jun 18, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 5, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 7, 2024, 12:50 PM EDT - 1 year ago

EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program

May 6, 2024, 9:10 AM EDT - 1 year ago

EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal

May 6, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Apr 2, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Mar 7, 2024, 12:29 PM EST - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript

Mar 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Mar 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

Feb 29, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

Feb 21, 2024, 8:36 AM EST - 1 year ago

EyePoint Is Betting The Bank On EYP-1901

Feb 3, 2024, 4:20 PM EST - 1 year ago

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Jan 31, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 10, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

Dec 20, 2023, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 7:55 AM EST - 1 year ago

EyePoint (EYPT) stock price went parabolic: brace for a pullback

rizzato Sep. 14 at 11:48 AM

$EYPT https://stockinvest.us/stock/EYPT

0 · Reply

rizzato Sep. 12 at 7:18 AM

$EYPT no comment that is a silent forum

1 · Reply

rizzato Sep. 11 at 8:02 PM

$EYPT again today at 15.45 volume was 842.000 pcs at 16.00 volume was 1.180.000 any idea ?

0 · Reply

rizzato Sep. 11 at 5:18 PM

$EYPT high volume someone is adding more at these price as soon as they will be ready we will continue our up movement

0 · Reply

Poet5 Sep. 11 at 5:08 PM

$EYPT Now, that was a nice 250K sh buy at 12:54PM. More to come! Watch!

0 · Reply

rizzato Sep. 11 at 8:56 AM

$EYPT hi Guido I realized that , there should be something coming soon . I ask and answer myself hahahahahahhaha

0 · Reply

rizzato Sep. 10 at 8:02 PM

$EYPT did anyone of you notice that are 3 days in a row that at the closing time there are around 200.000 pcs bought

0 · Reply

rizzato Sep. 10 at 7:38 PM

$EYPT even if is an healthy drop it was better to avoid it

0 · Reply

rizzato Sep. 10 at 5:01 PM

$EYPT for the moment it could be considered an healthy drop I was waiting for it

0 · Reply

rizzato Sep. 10 at 1:24 PM

anyone has the open order book 10 levels to post? $EYPT

0 · Reply

rizzato Sep. 10 at 5:37 AM

$EYPT https://stockinvest.us/stock/EYPT

0 · Reply

rizzato Sep. 9 at 7:03 PM

$EYPT probably the 2 investor conference were nice 16 coming soon

2 · Reply

Harpua_dumphuk Sep. 9 at 5:17 PM

$EYPT Loving the action. Such a small float that they can take it up and pin it at $ 30.00 or higher. The chart has zero resistance all the way to new 5 years highs.

3 · Reply

rizzato Sep. 9 at 7:00 AM

$EYPT what about today dropping again a little bit and then up again direction 16?

0 · Reply

rizzato Sep. 9 at 6:59 AM

$EYPT https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=EYPT#google_vignette

0 · Reply

rizzato Sep. 8 at 1:39 PM

$EYPT I have to ask the moderator to limit the posts in this forum because there are too many of them hahahahahahahhh

0 · Reply

rizzato Sep. 8 at 7:14 AM

Good morning everyone, let's take a look at the coming week. A small, healthy retracement before starting again. Retracement to 12.45 Retracement below 12 Continuation of the climb Continuation of the climb to target 16 Continuation of the target 17 Continuation of the higher targets what is your opinion ???????? $EYPT

0 · Reply

StockScanners Sep. 6 at 11:21 AM

$EYPT keep watch if this holds above 12.45

3 · Reply

Qora Sep. 5 at 10:44 PM

$EYPT take profits take profits

1 · Reply

KimboIce Sep. 5 at 8:02 PM

$EYPT

0 · Reply

rizzato Sep. 5 at 5:48 PM

$EYPT someone is for sure taking profit at that price but are you sure that will be the right thing to do? In Italy we say ‘vendi e pentiti’ I don’t think the up movement is finish Let’s see

1 · Reply

MasterG01 Sep. 5 at 5:18 PM

$EYPT reminder institutions and insuders own over 100% of the float...

0 · Reply

Market Cap	920.18M
Revenue (ttm)	43.27M
Net Income (ttm)	-130.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-302.45%
Debt to Equity Ratio	0.00

Volume	665,100
Avg Vol	715,428
Day's Range	N/A - N/A
Shares Out	68.93M
Stochastic %K	65%
Beta	1.93
Analysts	Strong Sell
Price Target	$31.92